NCT05903118 - A Phase I/II Study to Evaluate a SARS-CoV-2 mRNA Vaccine in Healthy Adults | Biotech Hunter

Enrollment

480

Participants

Timeline

Start Date

January 8, 2022

Primary Completion Date

September 1, 2022

Study Completion Date

July 19, 2023

Conditions

SARS-CoV-2

Interventions

BIOLOGICAL

RBMRNA-176

Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection

OTHER

Placebo

0.9% sodium chloride (normal saline) injection

Trial Locations (1)

Chengdu Xinhua Hospital affiliated to North Sichuan Medical College, Chengdu